Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
CAMLINFINE

Camlin Fine Sciences Share Price

 

 

Camlin Fine Sciences live price: ₹122.05. It opened at ₹131 vs previous close ₹130; intraday high/low: ₹131/₹121. The 50 & 200 DMA stand at ₹124.63/₹151.70.

Camlin Fine Sciences Performance

  • Today's Low
  • ₹121
  • Today's High
  • ₹131
  • 52 Week Low
  • ₹96
  • 52 Week High
  • ₹333
  • Open Price₹131
  • Previous Close₹130
  • Volume1,426,637
  • 50 DMA₹124.63
  • 100 DMA₹134.97
  • 200 DMA₹151.70

Camlin Fine Sciences Chart

Investment Returns

  • Over 1 Month -0.66%
  • Over 3 Month -17.48%
  • Over 6 Month -25.99%
  • Over 1 Year -49.88%

Smart Investing Starts Here Start SIP with Camlin Fine Sciences for Steady Growth!

Invest Now

Camlin Fine Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 84.9
  • PEG Ratio
  • 0.7
  • Market Cap Cr
  • 2,344
  • P/B Ratio
  • 2.7
  • Average True Range
  • 7.43
  • EPS
  • 0.64
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.98
  • RSI
  • 49.16
  • MFI
  • 69.3

Latest Stock News Updates

Camlin Fine Sciences Results Earnings Call for Q4FY26 & Full Year

Conference Call with Camlin Fine Sciences Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

Q4FY26 & FY26 Result Announced for Camlin Fine Sciences Ltd.

Specialty Chemicals company Camlin Fine Sciences announced Q4FY26 & FY26 results Q4FY26 Consolidated Financial Highlights: The company reported Revenue from operations of Rs 42,481.12 lakh for Q4FY26, showing a decline of 3.56% on a QoQ basis from Rs 44,051.07 lakh in Q3FY26 and a 1.57% decrease on a YoY basis compared to Rs 43,158.42 lakh in Q4FY25. Total Income for the quarter stood at Rs 44,872.34 lakh, representing a 1.25% growth over Q3FY26 (Rs 44,319.09 lakh) and a 1.34% increase over Q4FY25 (Rs 44,277.25 lakh). Loss before tax from continuing operations was Rs 526.27 lakh, compared to a loss of Rs 2,757.47 lakh in Q3FY26 and a profit of Rs 3,736.08 lakh in Q4FY25. Net Profit for the quarter surged to Rs 8,627.73 lakh, a significant turnaround from a net loss of Rs 3,710.29 lakh in Q3FY26 and an increase from a profit of Rs 11.00 lakh in Q4FY25. This surge was primarily driven by profit from discontinued operations. Earnings per share (Basic) for the quarter was Rs 4.59, compared to Rs (1.91) in Q3FY26 and Rs (0.04) in Q4FY25. FY26 Consolidated Financial Highlights: Revenue from operations for FY26 reached Rs 1,72,330.81 lakh, a growth of 5.81% compared to Rs 1,62,868.75 lakh in FY25. Total Income for the full year stood at Rs 1,75,210.04 lakh, up from Rs 1,64,384.94 lakh in the previous year. The Group reported a Net Profit for the year of Rs 2,354.32 lakh, compared to a net loss of Rs 15,811.94 lakh in FY25. Total Comprehensive Income for FY26 was Rs 2,698.04 lakh, against a loss of Rs 17,035.43 lakh in FY25. Q4FY26 Standalone Financial Highlights: Revenue from operations was Rs 18,351.65 lakh, down 16.17% on a QoQ basis from Rs 21,892.16 lakh in Q3FY26 and down 32.68% on a YoY basis from Rs 27,259.63 lakh in Q4FY25. Total Income for Q4FY26 was Rs 19,881.84 lakh, a decrease of 11.51% QoQ and 29.38% YoY. The company reported a Net Loss for the quarter of Rs 564.95 lakh, narrowing from a loss of Rs 1,299.66 lakh in Q3FY26, but down from a profit of Rs 1,561.84 lakh in Q4FY25. FY26 Standalone Financial Highlights: Revenue from operations for FY26 stood at Rs 83,791.82 lakh, a decline of 5.48% compared to Rs 88,649.13 lakh in FY25. The Standalone Net Loss for the year narrowed to Rs 3,296.62 lakh, compared to a loss of Rs 7,631.05 lakh in FY25. Business Highlights: Segment Performance: The Company's operations constitute a single business segment, namely Speciality Chemicals. Acquisition of Vinpai S.A.: The company acquired 83.82% stake in Vinpai S.A. during the year. The consideration was discharged by issuing 41,06,181 fresh equity shares at a premium of Rs 246.69 per share and the conversion of listed secured convertible bonds. A goodwill of Rs 16,810.5 lakh was recorded on this acquisition. Liquidation of Italian Subsidiary: Following a liquidation order for CFS Europe SpA, Italy, on March 17, 2026, an official liquidator was appointed. Consequent to the loss of control, a gain on derecognition of net liabilities amounting to Rs 10,290.51 lakh was recognized in profit from discontinued operations. Tariff Refund: The company recorded a refund receivable of Rs 1,035.09 lakh in standalone revenue and Rs 1,277.38 lakh (adjusted in materials cost) in consolidated results regarding tariffs paid under the International Emergency Economic Powers Act of USA. Management Changes: Mr. Pankaj Pandey has been appointed as the Chief Financial Officer (CFO) effective August 18, 2026. Mr. Santosh Parab, the current CFO, will be re-designated as President – Strategy and Global CFO on the same date. Fire Incident Impact: Consolidated results include an expected loss of Rs 609.37 lakh (net of insurance claim) related to a major fire incident at two blending units of CFS Do Brasil Industria, Comercio, Importacao e Exportacao de Aditivos Alimenticios LTDA. Result PDF

Q3FY26 Quarterly Result Announced for Camlin Fine Sciences Ltd.

Specialty Chemicals company Camlin Fine Sciences announced Q3FY26 results Financial Highlights: Revenue from operations: Rs 4,572 million against Rs 4,310.2 million during Q3FY25, change 6%. EBITDA: Rs 220.3 million against Rs 577.6 million during Q3FY25, change -62%. EBITDA Margin: 4.8% for Q3FY26. PBT: Rs -278.5 million against Rs 87 million during Q3FY25. PAT: Rs -279 million against Rs 15.5 million during Q3FY25. Business Highlights: Pricing pressure on Straights impacted the profitability Blends business maintains steady growth across key markets. CFS acquired a controlling stake in Vinpai on 30th November and contributed Rs 129 million in revenue in Q3FY26 Vanillin business was impacted by tariff-related challenges. Benefits of higher realization on the internal channel inventory of Vanillin in subsequent quarters due to the withdrawal of the tariff. Employee costs and other expenses remain under control, but increase due to the acquisition of Vinpai during the quarter EBITDA for the quarter was Rs. 307 mn, with a margin of 6.7%. Fire incident was reported at one unit in Brazil on February 7, 2026; loss assessment by the insurer is in progress, and operations at the unit are suspended. However, other unit continues to operate, alternative arrangements being made to service the customers, the quantum of loss not determinable at this stage. CFS Europe is likely to be liquidated. Losses of discontinued operations would be curtailed Outlook for the remaining financial year: Vanillin business expects to improve on realisations as well as volume with the withdrawal of the US tariff. Blends are likely to maintain growth momentum in all geographies despite challenges in CFS Brazil. Result PDF

Camlin Fine Sciences Financials

Camlin Fine Sciences Technicals

EMA & SMA

Current Price
₹122.05
-8.14 (-6.25%)
pointer
  • Bearish Moving Average 15
  • Bullish Moving Average 1
  • 20 Day
  • ₹123.15
  • 50 Day
  • ₹124.63
  • 100 Day
  • ₹134.97
  • 200 Day
  • ₹151.70

Resistance and Support

124.76 Pivot Speed
  • R3 138.72
  • R2 134.97
  • R1 128.51
  • S1 118.30
  • S2 114.55
  • S3 108.09

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Camlin Fine Sciences manufactures specialty chemicals, including antioxidants and aroma chemicals. The company operates facilities in India and internationally, serving industries such as food, feed, pharmaceuticals, and petrochemicals with high-quality, sustainable chemical solutions.

Camlin Fine Sciences has an operating revenue of Rs. 1,765.39 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of -2% needs improvement, ROE of 2% is fair but needs improvement. The company has a reasonable debt to equity of 29%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and around 9% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 25 which is a POOR score indicating inconsistency in earnings, a RS Rating of 12 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 46 indicates it belongs to a fair industry group of Chemicals-Basic and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Camlin Fine Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-26 Audited Results
2026-02-13 Quarterly Results
2025-11-10 Quarterly Results
2025-09-29 Preferential Issue of shares
2025-08-08 Quarterly Results

Camlin Fine Sciences Shareholding Pattern

48.03%
6.8%
0.94%
0%
28.27%
15.96%

Camlin Fine Sciences FAQs

Camlin Fine Sciences share price is ₹122 As on 30 May, 2026 | 11:01

The Market Cap of Camlin Fine Sciences is ₹2344.4 Cr As on 30 May, 2026 | 11:01

The P/E ratio of Camlin Fine Sciences is 84.9 As on 30 May, 2026 | 11:01

The PB ratio of Camlin Fine Sciences is 2.7 As on 30 May, 2026 | 11:01

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23